NO784002L - Fremgangsmaate til fremstilling av salter av benzodipyranforbindelser - Google Patents

Fremgangsmaate til fremstilling av salter av benzodipyranforbindelser

Info

Publication number: NO784002L
Authority: NO; Norway
Prior art keywords: salt; propyl; dioxo; dipyran; benzo
Prior art date: 1977-11-30

Application number

NO784002A

Other languages

English (en)

Norwegian (no)

Inventor

Hugh Cairns

Thomas Brian Lee

Anthony Howard Ingall

Kenneth Brown

Roger Edward Collingw Altouyan

Original Assignee

Fisons Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-11-30

Filing date

1978-11-28

Publication date

1979-05-31

1978-11-28 Application filed by Fisons Ltd filed Critical Fisons Ltd

1979-05-31 Publication of NO784002L publication Critical patent/NO784002L/no

Links

238000000034 method Methods 0.000 title claims description 13
238000002360 preparation method Methods 0.000 title claims description 11
150000001875 compounds Chemical class 0.000 title description 10
150000003839 salts Chemical class 0.000 claims description 38
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
150000001768 cations Chemical class 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 5
150000001767 cationic compounds Chemical class 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 5
229910001411 inorganic cation Inorganic materials 0.000 claims description 5
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 4
150000001408 amides Chemical class 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
150000002892 organic cations Chemical class 0.000 claims description 3
239000002904 solvent Substances 0.000 claims description 3
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims description 2
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
230000002209 hydrophobic effect Effects 0.000 claims description 2
159000000000 sodium salts Chemical class 0.000 claims description 2
239000007858 starting material Substances 0.000 claims description 2
BTHYDDWGEVSYPS-UHFFFAOYSA-L calcium;4,6-dioxo-10-propylpyrano[3,2-g]chromene-2,8-dicarboxylate Chemical group [Ca+2].O1C(C([O-])=O)=CC(=O)C2=C1C(CCC)=C1OC(C([O-])=O)=CC(=O)C1=C2 BTHYDDWGEVSYPS-UHFFFAOYSA-L 0.000 claims 1
239000000243 solution Substances 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 10
208000006673 asthma Diseases 0.000 description 9
239000007787 solid Substances 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
239000000427 antigen Substances 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
239000003380 propellant Substances 0.000 description 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
229960000265 cromoglicic acid Drugs 0.000 description 6
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 6
239000003814 drug Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000011282 treatment Methods 0.000 description 5
239000000443 aerosol Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000004147 Sorbitan trioleate Substances 0.000 description 3
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 3
201000009961 allergic asthma Diseases 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
159000000003 magnesium salts Chemical class 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
235000019337 sorbitan trioleate Nutrition 0.000 description 3
229960000391 sorbitan trioleate Drugs 0.000 description 3
WEQNUNAIQXHGHB-UHFFFAOYSA-N 4,6-dioxo-10-propylpyrano[3,2-g]chromene-2,8-dicarboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 WEQNUNAIQXHGHB-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010006482 Bronchospasm Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
-1 alkali metal salts Chemical class 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000007885 bronchoconstriction Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
159000000007 calcium salts Chemical group 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
150000004683 dihydrates Chemical class 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
208000021760 high fever Diseases 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005649 metathesis reaction Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
OTXHZHQQWQTQMW-UHFFFAOYSA-N (diaminomethylideneamino)azanium;hydrogen carbonate Chemical compound OC([O-])=O.N[NH2+]C(N)=N OTXHZHQQWQTQMW-UHFFFAOYSA-N 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
XDCMHOFEBFTMNL-UHFFFAOYSA-N 2-propylbenzene-1,3-diol Chemical compound CCCC1=C(O)C=CC=C1O XDCMHOFEBFTMNL-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WVKIFIROCHIWAY-UHFFFAOYSA-N hydron;2-(methylamino)acetic acid;chloride Chemical compound Cl.CNCC(O)=O WVKIFIROCHIWAY-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
231100000037 inhalation toxicity test Toxicity 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
150000004685 tetrahydrates Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicinal Preparation (AREA)

NO784002A 1977-11-30 1978-11-28 Fremgangsmaate til fremstilling av salter av benzodipyranforbindelser NO784002L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB4976177		1977-11-30
GB4976477		1977-11-30

Publications (1)

Publication Number	Publication Date
NO784002L true NO784002L (no)	1979-05-31

Family

ID=26266538

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO784002A NO784002L (no)	1977-11-30	1978-11-28	Fremgangsmaate til fremstilling av salter av benzodipyranforbindelser

Country Status (13)

Country	Link
JP (1)	JPS5490197A (fr)
AT (1)	AT363932B (fr)
AU (1)	AU516587B2 (fr)
DE (1)	DE2851440A1 (fr)
DK (1)	DK531478A (fr)
FI (1)	FI783635A7 (fr)
FR (1)	FR2410654A1 (fr)
IL (1)	IL56053A0 (fr)
LU (1)	LU80599A1 (fr)
NL (1)	NL7811486A (fr)
NO (1)	NO784002L (fr)
PT (1)	PT68846A (fr)
SE (1)	SE7812205L (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1230087A (fr) *	1967-08-17	1971-04-28

1978
- 1978-11-22 NL NL7811486A patent/NL7811486A/xx not_active Application Discontinuation
- 1978-11-27 IL IL56053A patent/IL56053A0/xx unknown
- 1978-11-27 AT AT0846878A patent/AT363932B/de not_active IP Right Cessation
- 1978-11-27 SE SE7812205A patent/SE7812205L/xx unknown
- 1978-11-28 DE DE19782851440 patent/DE2851440A1/de not_active Withdrawn
- 1978-11-28 FI FI783635A patent/FI783635A7/fi unknown
- 1978-11-28 NO NO784002A patent/NO784002L/no unknown
- 1978-11-28 DK DK531478A patent/DK531478A/da not_active Application Discontinuation
- 1978-11-29 LU LU80599A patent/LU80599A1/fr unknown
- 1978-11-29 PT PT68846A patent/PT68846A/pt unknown
- 1978-11-29 FR FR7833745A patent/FR2410654A1/fr not_active Withdrawn
- 1978-11-29 JP JP14669578A patent/JPS5490197A/ja active Pending
- 1978-11-30 AU AU42099/78A patent/AU516587B2/en not_active Expired

Also Published As

Publication number	Publication date
AU4209978A (en)	1979-06-07
AT363932B (de)	1981-09-10
FI783635A7 (fi)	1979-05-31
IL56053A0 (en)	1979-01-31
PT68846A (en)	1978-12-01
SE7812205L (sv)	1979-05-31
DK531478A (da)	1979-05-31
DE2851440A1 (de)	1979-05-31
AU516587B2 (en)	1981-06-11
LU80599A1 (fr)	1979-06-15
JPS5490197A (en)	1979-07-17
ATA846878A (de)	1981-02-15
FR2410654A1 (fr)	1979-06-29
NL7811486A (nl)	1979-06-01

Publication	Publication Date	Title
DE2943658C2 (fr)	1991-08-01
TWI516488B (zh)	2016-01-11	嘧啶并［６，１－ａ］異喹啉－４－酮化合物之結晶型
KR101210361B1 (ko)	2012-12-10	다형의 ｇａｂａａ 효능제
US3624103A (en)	1971-11-30	3-indoleacetohydroxamic acids
CH626612A5 (fr)	1981-11-30
US5696143A (en)	1997-12-09	Benz G! indazolyl derivatives for the treatment of inflammation
BG63874B1 (bg)	2003-04-30	Производни на индол-2,3-дион-3-оксим
FI71144B (fi)	1986-08-14	Foerfarande foer framstaellning av terapeutiskt aktiv 1-etyl-6-fluor-1,4-dihydro-4-oxo-(1-piperazinyl)-1,8-naftyridin-3-karboxylsyraseskvihydrat
NO317107B1 (no)	2004-08-09	Ny krystallmodifikasjon av torasemid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat
NO151287B (no)	1984-12-03	Analogifremgangsmaate for fremstilling av terapeutisk aktive 9-hydrazono-6,7,8,9-tetrahydro-4h-pyrido(1,2-a)-pyrimidinderivater
WO2003082806A1 (fr)	2003-10-09	Base de venlafaxine
MX2011000353A (es)	2011-02-22	Uso de derivados de indol como activadores del receptor nuclear asociado 1 para tratar la enfermedad de parkinson.
NO784002L (no)	1979-05-31	Fremgangsmaate til fremstilling av salter av benzodipyranforbindelser
US4315862A (en)	1982-02-16	Process for preparing cannabichromene
JP2511204B2 (ja)	1996-06-26	置換インド―ル
IL44056A (en)	1977-01-31	Theophylline-acetate salts of isoquinoline derivatives,their preparation and pharmaceutical compositions containing them
NO752192L (fr)	1976-03-25
US20110021589A1 (en)	2011-01-27	Imidazolic compounds and use thereof as alpha-2 adrenergic receptors
CA1112651A (fr)	1981-11-17	Sel de 2,8-dicarboxy-4,6-dioxy-10-propyl-4h,6h-benzo (1,2-b:5,4-b') dipyrane
JPS6222993B2 (fr)	1987-05-20
CN111620816B (zh)	2023-06-02	螺桨烷类衍生物、其制备方法、药物组合物和用途
US3901893A (en)	1975-08-26	New dihydro-lysergic acid derivative
NO761942L (fr)	1976-12-10
US4085116A (en)	1978-04-18	Novel chromone derivatives
NO155773B (no)	1987-02-16	Analogifremgangsmaate ved fremstilling av terapeutisk aktive 3-substituerte tetrahydropyrrolo (1,2-a) pyrimidinderivater.